 |
 |
      |
|
| Creating the next generation of cancer treatments |
 |
|
 |
PIPELINEArno has exclusive worldwide rights to develop and market three innovative, clinical-stage anti-cancer product candidates with unique mechanisms of action. These compounds include two targeted agents and one cytotoxic molecule that have the potential to be best- or first-in-class products for the treatment of hematologic malignancies and solid tumors.  AR-12 is a potentially first-in-class, orally available inhibitor of PDK1, a molecule in the PI3K/Akt pathway, and may also cause cell death through the induction of endoplasmic reticulum stress. We are currently conducting a multi-centered Phase I clinical study of AR-12 in adult patients with advanced or recurrent solid tumors or lymphoma. CLINICAL PROGRAM For information about the current clinical program, please Click Here AR-42 is an orally available, broad-spectrum deactylation inhibitor of both histone and non-histone proteins which play an important role in the regulation of gene expression, cell growth and survival. In preclinical studies, AR-42 has demonstrated greater potency and activity in solid and liquid tumors when compared to vorinostat (also known as SAHA and marketed as Zolinza® by Merck) and other deacetylase inhibitors. These data demonstrate the potent and differentiating activity of AR-42. Additionally, pre-clinical findings presented at the 2009 American Society of Hematology (ASH) and 2011 American Association for Cancer Research (AACR) Annual Meetings showed that AR-42 potently and selectively inhibits leukemic stem cells in acute myeloid leukemia, or AML. AR-42 is currently being studied in an investigator-initiated Phase I/IIa clinical study in adult patients with relapsed or refractory multiple myeloma, chronic lymphocytic leukemia or lymphoma. CLINICAL PROGRAM For information about the current clinical program, please Click Here AR-67 is a novel, third-generation camptothecin analogue that inhibits Topoisomerase I activity. In 2008, we completed a multi-centered, ascending-dose Phase I clinical trial of AR-67 in patients with advanced solid tumors. AR-67 is currently being studied in a Phase II clinical trial in patients with glioblastoma multiforme (GBM), a highly aggressive form of brain cancer. Arno is also initiating a Phase II clinical study of AR-67 as a potential treatment for colorectal cancer. CLINICAL PROGRAM For information about the current clinical program, please Click Here | | 
Arno Therapeutics, Inc. |
©2011 Arno Therapeutics, Inc. | Privacy Policy |